Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $19.00 Average Target Price from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received an average recommendation of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

Several research firms recently commented on LXEO. Oppenheimer reiterated an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, December 10th. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright decreased their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th. Finally, Raymond James Financial started coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price objective for the company.

Lexeo Therapeutics Price Performance

LXEO opened at $7.50 on Thursday. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $10.99. The business has a 50 day moving average price of $9.26 and a two-hundred day moving average price of $7.28. The company has a market capitalization of $547.43 million, a price-to-earnings ratio of -2.78 and a beta of 1.75.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.15. Equities analysts expect that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC raised its stake in shares of Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after purchasing an additional 6,216 shares in the last quarter. Ethic Inc. bought a new position in shares of Lexeo Therapeutics in the second quarter worth $44,000. Cerity Partners LLC bought a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth $50,000. Intech Investment Management LLC lifted its holdings in shares of Lexeo Therapeutics by 20.7% in the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after acquiring an additional 2,342 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Lexeo Therapeutics in the 2nd quarter worth about $60,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.